Chardan Capital reissued their buy rating on shares of The Medicines Company (NASDAQ:MDCO) in a research report report published on Tuesday. The firm currently has a $85.00 price target on the stock, up from their prior price target of $80.00.

Other analysts also recently issued research reports about the stock. CIBC set a $50.00 target price on shares of The Medicines in a report on Tuesday, May 23rd. Jefferies Group LLC reiterated a buy rating and issued a $54.00 target price (down previously from $62.00) on shares of The Medicines in a report on Thursday, August 10th. Cowen and Company reiterated a buy rating and issued a $54.00 target price (down previously from $61.00) on shares of The Medicines in a report on Thursday, August 10th. Zacks Investment Research upgraded shares of The Medicines from a hold rating to a buy rating and set a $41.00 target price for the company in a report on Tuesday, August 8th. Finally, TheStreet downgraded shares of The Medicines from a c- rating to a d rating in a report on Wednesday, August 9th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating to the company. The Medicines presently has a consensus rating of Buy and an average price target of $54.00.

Shares of The Medicines (MDCO) opened at 38.74 on Tuesday. The Medicines has a one year low of $30.80 and a one year high of $55.95. The company’s 50-day moving average price is $37.37 and its 200 day moving average price is $44.36. The stock’s market capitalization is $2.79 billion.

The Medicines (NASDAQ:MDCO) last posted its earnings results on Wednesday, August 9th. The company reported ($5.52) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.29) by $4.23. The Medicines had a negative net margin of 670.46% and a negative return on equity of 137.20%. The company had revenue of $18.74 million during the quarter, compared to analyst estimates of $29.64 million. During the same quarter last year, the business posted ($0.62) EPS. The firm’s revenue for the quarter was down 65.8% on a year-over-year basis. Analysts anticipate that The Medicines will post ($9.60) EPS for the current year.

TRADEMARK VIOLATION WARNING: “The Medicines Company (MDCO) Given Buy Rating at Chardan Capital” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The legal version of this article can be read at https://www.watchlistnews.com/the-medicines-company-mdco-given-buy-rating-at-chardan-capital/1531453.html.

A number of institutional investors have recently modified their holdings of MDCO. Piedmont Investment Advisors LLC boosted its position in shares of The Medicines by 265.5% in the second quarter. Piedmont Investment Advisors LLC now owns 15,604 shares of the company’s stock valued at $593,000 after buying an additional 11,335 shares in the last quarter. Ameritas Investment Partners Inc. boosted its position in shares of The Medicines by 4.2% in the second quarter. Ameritas Investment Partners Inc. now owns 6,058 shares of the company’s stock valued at $230,000 after buying an additional 243 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of The Medicines by 2.0% in the second quarter. The Manufacturers Life Insurance Company now owns 53,205 shares of the company’s stock valued at $2,023,000 after buying an additional 1,033 shares in the last quarter. Bluefin Trading LLC acquired a new position in shares of The Medicines during the second quarter valued at approximately $214,000. Finally, PointState Capital LP boosted its position in shares of The Medicines by 0.8% in the second quarter. PointState Capital LP now owns 1,103,966 shares of the company’s stock valued at $41,962,000 after buying an additional 8,866 shares in the last quarter.

The Medicines Company Profile

The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).

Analyst Recommendations for The Medicines (NASDAQ:MDCO)

Receive News & Ratings for The Medicines Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines Company and related companies with Analyst Ratings Network's FREE daily email newsletter.